The Effect of Myo-Inositol and Folic Acid (Inofolic) Supplementation on Fertility Outcomes in Infertile Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial

Polycystic ovary syndrome (PCOS) is a leading endocrine cause of anovulatory infertility. Insulin resistance is a key pathogenetic factor, and while metformin is a common treatment, alternative therapies like inositols are being explored. This study investigated the efficacy of Inofolic® (a combination of myo-inositol and folic acid) as an adjunct to standard treatment on fertility outcomes in infertile women with PCOS. In this randomized controlled trial, 100 infertile women with PCOS were allocated to either a control group (n=50) receiving standard treatment (metformin and cyclical progesterone) or an intervention group (n=50) receiving standard treatment plus Inofolic powder (2 sachets/day, 2000 mg myo-inositol and 200 mcg folic acid each) for three months. Primary outcomes were follicular development (size and count measured via serial transvaginal ultrasonography) and fertility rate (serum β-hCG positivity). Secondary outcomes included hormonal (FSH, LH, prolactin) and metabolic (blood glucose) parameters. The intervention group demonstrated a significantly greater increase in follicular size and a more favorable trajectory in follicular count over the three-month period compared to the control group (p < 0.001). While β-hCG positivity rates increased significantly over time in both groups, the final rates at the end of the study were not statistically different (22.9% in control vs. 24% in intervention, p > 0.05). No significant intergroup differences were observed in secondary hormonal or metabolic outcomes. Adjunctive Inofolic supplementation significantly improved follicular development indices in women with PCOS. However, it did not lead to a significantly higher pregnancy rate within the three-month study period compared to standard treatment alone, suggesting its primary benefit may be on optimizing folliculogenesis rather than immediate conception.

Authors

Institutions

Publication Details

Journal
Studies in Multidisciplinary Medical Research
Published
2025-08-08
DOI
https://doi.org/10.61882/smmr.202501.07.01
Primary Topic
Ovarian function and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Effect of Myo-Inositol and Folic Acid (Inofolic) Supplementation on Fertility Outcomes in Infertile Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial

Tayebeh Rashidian, Fatemeh Mirzamarjani, Mohamad Mozafari
Studies in Multidisciplinary Medical Research
Ovarian function and disorders
article

The Effect of Myo-Inositol and Folic Acid (Inofolic) Supplementation on Fertility Outcomes in Infertile Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial

Tayebeh Rashidian, Fatemeh Mirzamarjani, Mohamad Mozafari
article en

Abstract

Polycystic ovary syndrome (PCOS) is a leading endocrine cause of anovulatory infertility. Insulin resistance is a key pathogenetic factor, and while metformin is a common treatment, alternative therapies like inositols are being explored. This study investigated the efficacy of Inofolic® (a combination of myo-inositol and folic acid) as an adjunct to standard treatment on fertility outcomes in infertile women with PCOS. In this randomized controlled trial, 100 infertile women with PCOS were allocated to either a control group (n=50) receiving standard treatment (metformin and cyclical progesterone) or an intervention group (n=50) receiving standard treatment plus Inofolic powder (2 sachets/day, 2000 mg myo-inositol and 200 mcg folic acid each) for three months. Primary outcomes were follicular development (size and count measured via serial transvaginal ultrasonography) and fertility rate (serum β-hCG positivity). Secondary outcomes included hormonal (FSH, LH, prolactin) and metabolic (blood glucose) parameters. The intervention group demonstrated a significantly greater increase in follicular size and a more favorable trajectory in follicular count over the three-month period compared to the control group (p < 0.001). While β-hCG positivity rates increased significantly over time in both groups, the final rates at the end of the study were not statistically different (22.9% in control vs. 24% in intervention, p > 0.05). No significant intergroup differences were observed in secondary hormonal or metabolic outcomes. Adjunctive Inofolic supplementation significantly improved follicular development indices in women with PCOS. However, it did not lead to a significantly higher pregnancy rate within the three-month study period compared to standard treatment alone, suggesting its primary benefit may be on optimizing folliculogenesis rather than immediate conception.

Studies in Multidisciplinary Medical ResearchVol. 1(7)
Mashhad University of Medical Sciences (IR), Medical University of Ilam (IR), Ilam University (IR)
Openalex Percentile: Top 63%
Ovarian function and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.